...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on investigational drugs >An expert opinion on safinamide in Parkinson's disease.
【24h】

An expert opinion on safinamide in Parkinson's disease.

机译：关于沙芬酰胺治疗帕金森氏病的专家意见。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Dopamine replacement therapies (levodopa, dopamine receptor agonists, anticholinergics, monoamine oxidase B inhibitors, and catechol-O-methyltransferase inhibitors) remain the cornerstones of therapeutic interventions for Parkinson's disease (PD). Despite the treatment options for PD symptoms, a cure remains elusive. An optimal treatment would be one that combined relief in both motor and nonmotor symptoms with neuroprotective properties. Safinamide is an investigational drug for PD currently in development as add-on therapy to both dopamine agonists and levodopa. Safinamide is a unique molecule with a novel mode of action, targeting both dopaminergic and glutaminergic systems, and potentially provides motor symptom control. Preliminary results from experimental models suggest potential neuroprotective effects. Studies on the potential effects on nonmotor symptoms are ongoing. OBJECTIVE: To review the mechanism of action and pharmacokinetics, and to evaluate the available clinical safety and efficacy results of safinamide. METHODS: A search of the electronic database MEDLINE (PubMed, no time limits) was performed on 14 December 2007. The full text of all citations was obtained for review. Furthermore, two abstracts on safinamide published as proceedings of a European conference were reviewed. RESULTS/CONCLUSION: Safinamide is a promising investigational drug for PD with a novel mode of action. Early reports confirm the potential efficacy of safinamide in PD. Further studies on potential effects on cognition and neuroprotection are needed.
机译：背景：多巴胺替代疗法（左旋多巴，多巴胺受体激动剂，抗胆碱能药，单胺氧化酶B抑制剂和儿茶酚-O-甲基转移酶抑制剂）仍然是帕金森氏病（PD）治疗干预措施的基础。尽管有PD症状的治疗选择，但仍然无法治愈。一种最佳的治疗方法是将运动和非运动症状的缓解与神经保护特性相结合。沙芬酰胺是一种针对PD的研究药物，目前正在开发中，作为多巴胺激动剂和左旋多巴的附加疗法。沙芬酰胺是具有新颖作用方式的独特分子，靶向多巴胺能和谷氨酰胺能系统，并可能提供运动症状的控制。实验模型的初步结果表明潜在的神经保护作用。关于非运动症状的潜在影响的研究正在进行中。目的：综述作用机理和药代动力学，评价沙芬酰胺的临床安全性和有效性。方法：于2007年12月14日对MEDLINE电子数据库（PubMed，无时间限制）进行搜索。获得所有引文的全文以供审核。此外，还审查了欧洲会议纪要中发表的关于沙芬酰胺的两个摘要。结果/结论：沙芬酰胺是一种有前途的PD研究药物，具有新颖的作用方式。早期报道证实了沙芬胺在PD中的潜在疗效。需要进一步研究对认知和神经保护的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号